EBMT 2024 | Comparing the efficacy of salvage therapies in adult B-ALL: a retrospective real-world study
Alex Rampotas
• 16 Apr 2024
Alex Rampotas, MD, University College London, London, UK, briefly discusses the findings of a UK retrospective real-world study investigating the efficacy of different salvage therapies for adult patients with B-cell acute lymphoblastic leukemia (B-ALL) in the post-transplant relapsed setting. CAR T-cell therapy was found to be a superior salvage therapy approach, outperforming novel agents such as blinatumomab and tyrosine kinase inhibitors (TKIs). This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
